• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Launch One Acquisition Corp.

    11/14/24 1:34:17 PM ET
    $LPAA
    Get the next $LPAA alert in real time by email
    SC 13G 1 lpaa_111424.htm AQR CAPITAL MANAGEMENT LLC lpaa_111424.htm
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    Launch One Acquisition Corp.
    (Name of Issuer)
    Class A ordinary shares, par value $0.0001 per share
    (Title of Class of Securities)
    G5S86M100
    (CUSIP Number)
    September 30, 2024
    (Date of Event which Requires Filing of this Statement)
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [X] Rule 13d-1(b)
    [   ] Rule 13d-1(c)
    [   ] Rule 13d-1(d)
    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see Instructions).
    CUSIP No.: G5S86M100
           
    1
    NAME OF REPORTING PERSON
    AQR Capital Management, LLC
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware, USA
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    6
    SHARED VOTING POWER
    2,024,296
    7
    SOLE DISPOSITIVE POWER
    8
    SHARED DISPOSITIVE POWER
    2,024,296
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    2,024,296
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    8.8%
    12
    TYPE OF REPORTING PERSON
    IA
    CUSIP No.: G5S86M100
           
    1
    NAME OF REPORTING PERSON
    AQR Capital Management Holdings, LLC
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware, USA
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    6
    SHARED VOTING POWER
    2,024,296
    7
    SOLE DISPOSITIVE POWER
    8
    SHARED DISPOSITIVE POWER
    2,024,296
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    2,024,296
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    8.8%
    12
    TYPE OF REPORTING PERSON
    HC
    CUSIP No.: G5S86M100
           
    1
    NAME OF REPORTING PERSON
    AQR Arbitrage, LLC
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware, USA
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    6
    SHARED VOTING POWER
    2,024,296
    7
    SOLE DISPOSITIVE POWER
    8
    SHARED DISPOSITIVE POWER
    2,024,296
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    2,024,296
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    8.8%
    12
    TYPE OF REPORTING PERSON
    IA
    CUSIP No.: G5S86M100
    ITEM 1(a). NAME OF ISSUER:
    Launch One Acquisition Corp.
    ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
    180 Grand Avenue, Suite 1530, Oakland,CA 94612
    ITEM 2(a). NAME OF PERSON FILING:
    (1) AQR Capital Management, LLC
    (2) AQR Capital Management Holdings, LLC
    (3) AQR Arbitrage, LLC
    ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
    (1) ONE GREENWICH PLAZA, GREENWICH, CT 06830
    (2) ONE GREENWICH PLAZA, GREENWICH, CT 06830
    (3) ONE GREENWICH PLAZA, GREENWICH, CT 06830
    ITEM 2(c). CITIZENSHIP:
    (1) Delaware, USA
    (2) Delaware, USA
    (3) Delaware, USA
    ITEM 2(d). TITLE OF CLASS OF SECURITIES:
    Class A ordinary shares, par value $0.0001 per share
    ITEM 2(e). CUSIP NUMBER:
    G5S86M100
    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SECTION 240.13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS A:
    (a)
    [ ]
    Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78c);
    (b)
    [ ]
    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)
    [ ]
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)
    [ ]
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
    (e)
    [X]
    An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
    (f)
    [ ]
    An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);
    (g)
    [X]
    A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
    (h)
    [ ]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)
    [ ]
    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)
    [ ]
    A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J);
    (k)
    [ ]
    Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d1(b)(1)(ii)(J), please specify the type of institution:
    ITEM 4. OWNERSHIP
    (a) Amount beneficially owned:
    2,024,296
    (b) Percent of class:
    8.8%
    (c) Number of shares as to which the person has:
    (i) sole power to vote or to direct the vote:
    (ii) shared power to vote or to direct the vote:
    AQR Capital Management, LLC : 2,024,296

    AQR Capital Management Holdings, LLC : 2,024,296

    AQR Arbitrage, LLC : 2,024,296
    (iii) sole power to dispose or direct the disposition of:
    (iv) shared power to dispose or to direct the disposition of:
    AQR Capital Management, LLC : 2,024,296

    AQR Capital Management Holdings, LLC : 2,024,296

    AQR Arbitrage, LLC : 2,024,296
    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].
    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
    This Item 6 is not applicable.
    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
    See Item 2(a) above.
    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
    This Item 8 is not applicable.
    ITEM 9. NOTICE OF DISSOLUTION OF GROUP:
    This Item 9 is not applicable.
    ITEM 10. CERTIFICATION:
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
    CUSIP No.: G5S86M100
    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    November 14 2024
    AQR Capital Management, LLC
    By:
    /s/ Henry Parkin
    Name:
    Henry Parkin
    Title:
    Authorized Signatory
    November 14 2024
    AQR Capital Management Holdings, LLC
    By:
    /s/ Henry Parkin
    Name:
    Henry Parkin
    Title:
    Authorized Signatory
    November 14 2024
    AQR Arbitrage, LLC
    By:
    /s/ Henry Parkin
    Name:
    Henry Parkin
    Title:
    Authorized Signatory
    Attention — Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).
    CUSIP No.: G5S86M100
    AQR Capital Management Holdings, LLC, AQR Capital Management, LLC, and AQR Arbitrage, LLC hereby agree that this Schedule 13G is filed on behalf of each of the parties. AQR Capital Management, LLC is a wholly owned subsidiary of AQR Capital Management Holdings, LLC. AQR Arbitrage, LLC is deemed to be controlled by AQR Capital Management, LLC.

    Get the next $LPAA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LPAA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $LPAA
    SEC Filings

    View All

    SEC Form 10-K filed by Launch One Acquisition Corp.

    10-K - Launch One Acquisition Corp. (0002015502) (Filer)

    3/27/26 4:20:16 PM ET
    $LPAA

    SEC Form 425 filed by Launch One Acquisition Corp.

    425 - Launch One Acquisition Corp. (0002015502) (Subject)

    3/26/26 4:06:19 PM ET
    $LPAA

    Launch One Acquisition Corp. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits

    8-K - Launch One Acquisition Corp. (0002015502) (Filer)

    3/26/26 4:05:08 PM ET
    $LPAA

    $LPAA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Minovia Therapeutics Announces Two New U.S. Patents Granted, Strengthening Its Mitochondrial Augmentation Therapy Platform

    HAIFA, Israel, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. ("Minovia" or the "Company"), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, today announced that it has been granted two new U.S. patents that further expand and strengthen its global intellectual property portfolio supporting its proprietary Mitochondrial Augmentation Therapy (MAT) platform. The newly granted patents cover mitochondrial augmentation therapy for primary mitochondrial diseases and mitochondrial augmentation therapy for renal diseases, providing extended protection for Minovia's core platform technology. Corresponding

    1/13/26 9:51:59 AM ET
    $LPAA

    Minovia Therapeutics Mitochondrial Augmentation Technology to be Featured in Presentation and Workshop at the 67th ASH Annual Meeting and Exposition

    HAIFA, Israel, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. ("Minovia" or the "Company"), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, announces that data collected by research teams at Memorial Sloan Kettering Cancer Center (MSK) and Shaare Zedek Medical Center (SZMC) featuring the Company's mitochondrial augmentation technology in myelodysplastic syndrome (MDS) will be presented at the 67th American Society of Hematology's (ASH) Annual Meeting and Exposition on December 6-9, 2025 in Orlando, FL. The data will be featured in an oral presentation to be held on Saturday, Dec 6, 2PM ET (abs25-

    11/20/25 8:30:00 AM ET
    $LPAA

    Minovia Therapeutics Receives FDA Orphan Drug Designation for MNV-201 in Myelodysplastic Syndrome

    HAIFA, Israel, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. ("Minovia" or the "Company"), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to the Company's lead investigational compound, MNV-201 for Myelodysplastic Syndrome (MDS), a serious age-related hematopoietic disease. This designation is in addition to the existing FDA Fast Track Designation in MDS, as well as both Fast Track and Rare Pediatric Disease Designations for MNV-201 in the treatment of Pearson Syndrome. "We continue to receive

    10/15/25 7:30:00 AM ET
    $LPAA

    $LPAA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Launch One Acquisition Corp.

    SC 13G - Launch One Acquisition Corp. (0002015502) (Subject)

    11/14/24 9:03:16 PM ET
    $LPAA

    SEC Form SC 13G filed by Launch One Acquisition Corp.

    SC 13G - Launch One Acquisition Corp. (0002015502) (Subject)

    11/14/24 5:40:31 PM ET
    $LPAA

    SEC Form SC 13G filed by Launch One Acquisition Corp.

    SC 13G - Launch One Acquisition Corp. (0002015502) (Subject)

    11/14/24 1:34:17 PM ET
    $LPAA